Guillermo Garcia-Manero
Guillermo Garcia-Manero
Adresse e-mail validée de
Citée par
Citée par
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Revised international prognostic scoring system for myelodysplastic syndromes
PL Greenberg, H Tuechler, J Schanz, G Sanz, G Garcia-Manero, F Solé, ...
Blood, The Journal of the American Society of Hematology 120 (12), 2454-2465, 2012
Clinical effect of point mutations in myelodysplastic syndromes
R Bejar, K Stevenson, O Abdel-Wahab, N Galili, B Nilsson, ...
New England Journal of Medicine 364 (26), 2496-2506, 2011
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa, G Garcia-Manero, FJ Giles, R Mannari, D Thomas, S Faderl, ...
Blood 103 (5), 1635-1640, 2004
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
H Kantarjian, Y Oki, G Garcia-Manero, X Huang, S O'Brien, J Cortes, ...
Blood 109 (1), 52-57, 2007
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
O Abdel-Wahab, A Mullally, C Hedvat, G Garcia-Manero, J Patel, ...
Blood, The Journal of the American Society of Hematology 114 (1), 144-147, 2009
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, ...
Cancer cell 22 (2), 153-166, 2012
Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas, S Faderl, J Cortes, S O'Brien, FJ Giles, SM Kornblau, ...
Blood 103 (12), 4396-4407, 2004
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international …
J Schanz, H Tüchler, F Solé, M Mallo, E Luño, J Cervera, I Granada, ...
Journal of Clinical Oncology 30 (8), 820, 2012
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda, S O’Brien, S Wen, S Faderl, G Garcia-Manero, D Thomas, ...
Journal of clinical oncology 23 (18), 4070-4078, 2005
Myelodysplastic syndromes
PL Greenberg, NS Young, N Gattermann
ASH Education Program Book 2002 (1), 136-161, 2002
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: predictive prognostic models for outcome
H Kantarjian, S O'brien, J Cortes, F Giles, S Faderl, E Jabbour, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2006
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia
DA Thomas, S Faderl, S O'Brien, C Bueso‐Ramos, J Cortes, ...
Cancer 106 (7), 1569-1580, 2006
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
G Garcia-Manero, HM Kantarjian, B Sanchez-Gonzalez, H Yang, ...
Blood 108 (10), 3271-3279, 2006
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
H Ling, R Spizzo, Y Atlasi, M Nicoloso, M Shimizu, RS Redis, N Nishida, ...
Genome research 23 (9), 1446-1461, 2013
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
H Kantarjian, M Talpaz, S O'Brien, G Garcia-Manero, S Verstovsek, ...
Blood 103 (8), 2873-2878, 2004
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
H Kantarjian, S O'Brien, F Ravandi, J Cortes, J Shan, JM Bennett, A List, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
G Garcia-Manero, H Yang, C Bueso-Ramos, A Ferrajoli, J Cortes, ...
Blood, The Journal of the American Society of Hematology 111 (3), 1060-1066, 2008
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
R Bejar, A Lord, K Stevenson, M Bar-Natan, A Pérez-Ladaga, J Zaneveld, ...
Blood, The Journal of the American Society of Hematology 124 (17), 2705-2712, 2014
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H Yang, C Bueso-Ramos, C DiNardo, MR Estecio, M Davanlou, QR Geng, ...
Leukemia 28 (6), 1280-1288, 2014
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20